The Division of Cancer Treatment and Diagnosis (DCTD) is pioneering advancements in cancer treatment by developing innovative diagnostics, therapies, and research initiatives in collaboration with academia and industry. Their efforts center on a personalized approach, utilizing biomarkers and therapeutics tailored to each patient's unique pathology and genetic profile. Shifting from the traditional single-drug therapies, DCTD’s NCI-60 ComboMATCH initiative explores novel combinations of drugs for comprehensive treatment.
They're also driving progress in finding novel therapies for colorectal cancer, Acute Lymphoblastic Leukemia, and rare melanomas. DCTD facilitates this via strategic partnerships with entities like the National Clinical Trials Network and the NCI Patient-Derived Models Repository. Technological advancements through the Quantitative Imaging Network and Specialized Programs of Research Excellence enhance diagnostic precision and encourage interdisciplinary research. DCTD's dedication to translating research into clinical applications is transforming cancer treatment and offering hope to millions.
Full article here: https://medium.com/@lawsuithelpdesk/revolutionary-advances-in-cancer-treatment-unveiling-the-groundbreaking-work-of-dctd-9fbe6d7c9d3b